Mylan Strikes Back At Lilly In Strattera Patent Feud

Law360, New York (October 9, 2007, 12:00 AM EDT) -- Mylan Pharmaceuticals Inc. swiped back at Eli Lilly & Co. in an infringement battle over a patent for the attention deficit hyperactivity disorder treatment Strattera, denying that Lilly's claims are valid and enforceable and asserting a counterclaim that it has suffered irreparable harm to its reputation as a result of Lilly's suit.

In an amended answer and counterclaim filed Monday in the U.S. District Court for the District of New Jersey, Mylan rejected the claims asserted in Lilly's first amended complaint, filed Sept. 5, saying Lilly...
To view the full article, register now.